Study record · Pemvidutide
MOMENTUM: Pemvidutide Phase 2 obesity trial
Mean loss 10.3%, 11.2%, 15.6% vs 2.2% placebo; at 2.4 mg, 51.8% achieved ≥15% and 32.1% ≥20% weight loss.
Key result
Mean loss 10.3%, 11.2%, 15.6% vs 2.2% placebo; at 2.4 mg, 51.8% achieved ≥15% and 32.1% ≥20% weight loss.
Study details
Study designRandomized, placebo-controlled trial
PhasePhase 2
PopulationAdults with obesity or overweight plus ≥1 obesity-related comorbidity
Sample size391
RouteSubcutaneous
Regimen / exposure1.2, 1.8 or 2.4 mg once weekly
Duration48 weeks
ComparatorPlacebo
Primary endpoint / questionPercent body-weight change
Safety resultConference report; detailed safety interpretation requires full dataset/publication.
Key limitationsConference abstract rather than full peer-reviewed article; weight-loss programme later shifted strategic emphasis toward liver disease.
Registry / identifierMOMENTUM